Cancer Epidemiology最新文献

{"title":"Temporal trends in AML incidence and mortality, with a focus on AML-related deaths among patients with myelodysplastic syndromes in the United States, 1999–2023","authors":"Natalie A. Akoto ,&nbsp;Albert E. Orhin ,&nbsp;Denise Eke Chukwu ,&nbsp;Albert Gyato ,&nbsp;Simon Egyin ,&nbsp;Maame Yaa Idun ,&nbsp;Kwabena Owusu Aninkora","doi":"10.1016/j.canep.2025.102960","DOIUrl":"10.1016/j.canep.2025.102960","url":null,"abstract":"<div><h3>Background</h3><div>Myelodysplastic syndromes (MDS) are bone marrow disorders that often affect older adults and can lead to acute myeloid leukemia (AML), a more aggressive cancer. While this progression is well known, national trends in AML-related deaths, specifically among patients with MDS, have not been well described.</div></div><div><h3>Methods</h3><div>Using CDC WONDER death certificate data from 1999 to 2023, we identified adults aged 25 years and above who died from AML with MDS listed as a contributing cause. We analyzed demographics, place of death, and trends over time. Age-adjusted mortality rates were calculated and stratified by sex, race, geography, and urbanization. We also examined national trends in AML incidence and mortality-to-incidence ratios (MIR).</div></div><div><h3>Results</h3><div>AML incidence was 5.8 per 100,000, rising slightly over time (AAPC + 0.5 %; 95 % CI: 0.25–0.70). Among 16,979 AML-related deaths in people with MDS, most were male (61.6 %), White (91.8 %), and aged ≥ 75 years. Nearly half died in hospitals, while &lt; 1 % underwent autopsies. The age-adjusted mortality rate was 0.5 per 100,000 in males and 0.2 in females (p &lt; 0.0001). Mortality declined overall (AAPC − 1.16 %; 95 % CI: − 1.75 to − 0.57), with the sharpest drop between 2021 and 2023 (APC − 17.12 %, 95 % CI: − 22.61 to − 9.20). Improvements were most notable in urban areas and among White patients.</div></div><div><h3>Conclusion</h3><div>AML-related mortality in MDS patients has declined over the past 25 years, likely reflecting progress in treatment and supportive care. However, disparities persist. More equitable access to advanced therapies is needed to ensure all patients benefit from recent advances.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102960"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term air pollution exposure and mortality outcomes in colorectal cancer patients: Evidence from a multicenter longitudinal study","authors":"Chih-Wen Wang ,&nbsp;Pinpin Lin ,&nbsp;Yu-Cheng Chen ,&nbsp;Yueh-Hsia Luo ,&nbsp;Chih-Da Wu ,&nbsp;Ching-Chun Li ,&nbsp;Chun-Hung Richard Lin","doi":"10.1016/j.canep.2025.102948","DOIUrl":"10.1016/j.canep.2025.102948","url":null,"abstract":"<div><h3>Background</h3><div>Limited evidence exists regarding the relationship between air pollution and all-cause mortality in colorectal cancer stratified by clinical stages.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, initiated in 2010, we included patients with pathologically confirmed colorectal carcinoma. Each participant's address was geocoded to the corresponding village/borough or township, for accurate matching with estimated air pollution concentrations. The risk of all-cause mortality was assessed using Kaplan–Meier analysis and Cox proportional hazards regression models.</div></div><div><h3>Results</h3><div>Our study enrolled 5126 colorectal cancer patients, with a median survival time of 72.0 months. Higher exposures were associated with greater all-cause mortality: PM_2.5₅ tertile 3 vs tertile 1—HR 1.32 (95 % CI 1.14–1.52) and SO₂ tertile 3 vs tertile 1—HR 1.22 (95 % CI 1.06–1.40). Stage-stratified results showed PM_2.5 remained significant in stages 0–I (HR 1.62, 95 % CI 1.01–2.58) and III (HR 1.39, 95 % CI 1.11–1.73), whereas SO₂ was significant in stages II (HR 1.62, 95 % CI 1.03–2.53) and III (HR 1.34, 95 % CI 1.07–1.67). In multiplicative interactions, each unit increase in PM_2.5 was linked to a 1 % higher hazard (HR = 1.01; 95 % CI, 1.01–1.02), and each unit increase in SO₂ to a 5 % higher hazard (HR = 1.05; 95 % CI, 1.04–1.05). When stage was included additively, the per-unit effects were larger—7 % for PM_2.5 (HR = 1.07; 95 % CI, 1.05–1.10) and 14 % for SO₂ (HR = 1.14; 95 % CI, 1.11–1.17). Overall, pollutant levels and clinical stage jointly heightened all-cause mortality.</div></div><div><h3>Conclusions</h3><div>Elevated PM_2.5 and SO₂ exposures were significantly associated with higher all-cause mortality, with effect sizes varying by stage and generally stronger in stages 0–I and II–III. Clinical stage interacted both associations, and joint exposure–stage categories showed higher risks, underscoring the need to reduce pollution exposure in high-risk patients.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102948"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of vaccine-induced immunity to hepatitis B in cancer patients: A 13-year analysis in a quaternary oncological center","authors":"Mariana Cavalheiro Magri ,&nbsp;Victória Gonçalves de Paula ,&nbsp;Marina Rossi de Camargo Pinto ,&nbsp;Débora Bignotto Rosane Battaglia ,&nbsp;Rafael de Oliveira ,&nbsp;Gustavo Manoel Ferreira ,&nbsp;Fátima Mitiko Tengan ,&nbsp;Edson Abdala","doi":"10.1016/j.canep.2025.102946","DOIUrl":"10.1016/j.canep.2025.102946","url":null,"abstract":"<div><h3>Background</h3><div>Hepatitis B virus reactivation may occur in cancer patients, leading to liver damage and early discontinuation of treatment. To evaluate vaccine-induced immunity to hepatitis B, this study investigated the prevalence of anti-HBs antibodies from patients with solid tumors or hematological malignancies.</div></div><div><h3>Methods</h3><div>All cancer patients who underwent serological testing for anti-HBs from 2011 to 2023 and had negative anti-HBc results at the Instituto do Cancer do Estado de Sao Paulo, Brazil, were included. The prevalence of vaccine-induced immunity to hepatitis B during those years was assessed by using linear regression. Characteristics associated with presence of anti-HBs and anti-HBs titers (strongly positive: ≥ 100 IU/L; weakly positive: 10–99 IU/L) were evaluated by using multivariable logistic regression.</div></div><div><h3>Results</h3><div>A total of 23,854 patients were evaluated, 17,249 with solid tumors and 5114 with hematological malignancies. The prevalence of vaccine-induced immunity to hepatitis B was 22.1 %, with a significant linear increase over time (p &lt; 0.001). The presence of vaccine-induced immunity to hepatitis B was associated with younger age (OR=7.23, 95 % CI: 6.55–7.98), female sex (OR=1.25, 95 % CI: 1.15–1.36), non-white patients (OR=1.13, 95 % CI: 1.04–1.22), and patients with hematological malignancies (OR=1.16, 95 %CI: 1.07–1.27). Additionally, the variables younger age (OR=1.64, 95 % CI: 1.39–1.94) and female sex (OR=1.39, 95 % CI: 1.20–1.60) were associated with strongly protective anti-HBs titers (≥ 100 IU/L).</div></div><div><h3>Conclusions</h3><div>This finding indicates that approximately one-quarter of a large population with cancer was protected against HBV infection through serological evidence of anti-HBs. Preventive strategies are needed for cancer patients, who may benefit from hepatitis B vaccination.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102946"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Human Papillomavirus in Arica and Antofagasta, in the north of Chile","authors":"María Jesús Acuña ,&nbsp;Edgardo Mancilla ,&nbsp;Dania Acuña ,&nbsp;Giuliano Bernal","doi":"10.1016/j.canep.2025.102913","DOIUrl":"10.1016/j.canep.2025.102913","url":null,"abstract":"<div><h3>Background</h3><div>Cervical cancer is primarily caused by the Human Papillomavirus (HPV). Despite all the advances in early detection of HPV infection, cervical cancer remains one of the most common types of cancer in women, with a high presence in Latin America. We previously reported on the prevalence of HPV in the Coquimbo region, so the objective of this study was to determine the frequency of HPV in women in the Antofagasta and Arica regions of northern Chile.</div></div><div><h3>Methods</h3><div>We analyzed 823 cervical samples from women aged 15–79 who attended gynecological checkups during 2024 to detect HPV genotypes using qPCR. Of these, 199 come from Arica and 624 from Antofagasta, in northern Chile.</div></div><div><h3>Results</h3><div>The overall HPV positivity rate was 19.20 %; 23.62 % in Arica and 17.79 % in Antofagasta. The HR-HPV positivity rates in the G1 (15–29 years) and G2 (30–79 years) age groups were 30.92 % and 16.54 %, respectively. The most prevalent genotypes of HPV infection among our entire population were HPV16, HPV 31, and HPV52. Single infection (75.95 %) was the main HPV infection pattern observed in the entire group, followed by double or multiple infection (24.05 %), which was similar in Groups 1 and 2, where the prevalence of single infection was 72.34 % and 77.48 %, respectively.</div></div><div><h3>Conclusion</h3><div>The prevalence of HPV infections in women in the Arica and Antofagasta regions appears lower than that previously reported for Coquimbo, but similar to that reported in Chile by the Ministry of Health. This reflects the great heterogeneity of HPV prevalence in our vast country. On the other hand, molecular detection of 14 HR-HPV genotypes is important because it will not only help women avoid cervical cancer, but could also inform the introduction of new vaccines targeting a broader spectrum of HR-HPV.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102913"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation barriers to lung cancer screening: Conceptual misconceptions and the importance of seeking synergy with smoking cessation","authors":"Arn Migowski","doi":"10.1016/j.canep.2025.102957","DOIUrl":"10.1016/j.canep.2025.102957","url":null,"abstract":"","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102957"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145497557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden and international trends of laryngeal cancer incidence: A population-based study of recorded data and national estimates","authors":"Amanda Ramos da Cunha ,&nbsp;Harriet Rumgay ,&nbsp;Jerome Vignat ,&nbsp;Mathieu Laversanne ,&nbsp;Murielle Colombet ,&nbsp;Maria Paula Curado ,&nbsp;Gail Garvey ,&nbsp;Sarbani Ghosh-Laskar ,&nbsp;Brian O’Sullivan ,&nbsp;Shama Virani ,&nbsp;Isabelle Soerjomataram ,&nbsp;Marion Piñeros","doi":"10.1016/j.canep.2025.102935","DOIUrl":"10.1016/j.canep.2025.102935","url":null,"abstract":"<div><div>Laryngeal cancer shows considerable variation in global incidence, which has primarily been studied through national estimates. This study aims to analyse the global incidence of laryngeal cancer, comparing estimated and high-quality recorded data, and examine temporal trends to inform targeted prevention strategies. Estimated incidence rates for 2022 were obtained from the GLOBOCAN 2022 database for 185 countries. Recorded incidence data from population-based cancer registries (PBCRs) for the five-years period 2013–2017 were sourced from Cancer Incidence in Five Continents (CI5-XII). Temporal trends and the Estimated Annual Percent Change were assessed for 34 countries using the Global Cancer Observatory – Cancer Over Time database. The highest estimated age-standardized incidence rates (ASIRs) were observed in Cuba, Moldova, and Romania, particularly among males: 14.8, 12.2, and 10.3 per 100,000, respectively. Recorded data showed significant regional variability, with the highest ASIRs for males in Pskov, Russia (13.3 per 100,000) and the Azores, Portugal (11.8 per 100,000). Most countries exhibited a decline in laryngeal cancer rates among males, while trends among females remained largely stable. Our findings underscore the importance of PBCRs in identifying high-risk populations for developing laryngeal cancer. While national estimates are essential for understanding the global distribution of laryngeal cancer and other malignancies, they may overlook subnational variations. Expanding the coverage and quality of PBCRs is crucial for improving cancer surveillance and enhancing prevention and control efforts at national and global level.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102935"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient demographic and prognostic factors of vulvar squamous cell carcinoma: A National Cancer Database Study","authors":"Grace Folino ,&nbsp;Elizabeth Byrne ,&nbsp;Mya Hendry ,&nbsp;Peter Silberstein ,&nbsp;Marco DiBlasi","doi":"10.1016/j.canep.2025.102933","DOIUrl":"10.1016/j.canep.2025.102933","url":null,"abstract":"<div><h3>Background</h3><div>Vulvar Squamous Cell Carcinoma (VSCC) incidence rates and clinical outcomes are correlated with demographic factors, but no study expansively investigates demographic and prognostic factors of VSCC in relation to survival in the post-Gardasil era. This study aims to investigate underlying disparities in VSCC and correlate these factors with survival.</div></div><div><h3>Methods</h3><div>Patients were identified from the National Cancer Database using ICD-10 codes specific for vulvar structures, ICD-O-3 histology codes for squamous cell carcinoma and pre-malignant vulvar intraepithelial neoplasia Grade III (VIN3), and patient data from 2007 to 2021. Statistical analyses utilized IBM SPSS and GraphPad Prism to determine variable frequency with cross analysis and Chi-Squared tests, Kaplan Meier Survival Curves with Log-Rank Pairwise Comparison, and Cox Proportional Hazards Regression Models.</div></div><div><h3>Results</h3><div>The total patient population was 58,732 patients after inclusion criteria. The median age of diagnosis was 64.0 years old. Significant prognostic factors resulting in better survival included VIN3 histology, lower Charlson-Deyo Score, Black race, receiving care from Academic/Research Programs, private insurance, and median income greater than $63,000. Surgical procedures were significant in improving survival. Black patients are diagnosed younger than White and Other races. A histology type of VIN3 was associated with increased survival time, indicating early identification and treatment for better outcomes.</div></div><div><h3>Conclusion</h3><div>Key demographic and prognostic factors that influence survival were identified across the VSCC population. This study may serve as a tool in reevaluation of current gynecological screening protocols to promote early diagnosis and management for the entire VSCC patient population.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102933"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer incidence and mortality in Italy, 2013–2017","authors":"Andrea Tittarelli ,&nbsp;Sabrina Fabiano ,&nbsp;Viviana Perotti ,&nbsp;Maurizio Zarcone ,&nbsp;Maria Teresa Pesce ,&nbsp;Alessio Gili ,&nbsp;Fabrizio Stracci ,&nbsp;Walter Mazzucco ,&nbsp;Luigino Dal Maso ,&nbsp;Emanuele Crocetti ,&nbsp;Riccardo Capocaccia ,&nbsp;Giovanna Tagliabue ,&nbsp;Paolo Contiero ,&nbsp;AIRTUM Working Group","doi":"10.1016/j.canep.2025.102905","DOIUrl":"10.1016/j.canep.2025.102905","url":null,"abstract":"<div><div>The demographic transition, together with changes in lifestyles and the exposure to other risk factors, contributed to a rising burden of chronic degenerative diseases, including cancer, in Italy. We provided updated figures on cancer incidence and mortality in Italy during the period 2013–2017, using data provided by 34 population-based cancer registries from the AIRTUM network. Age-standardized incidence rates (ASRs) and age-standardized mortality rates (ASMRs) per 100,000 were estimated, stratified by sex, cancer site or type, and macroarea. The cumulative risk (number of individuals who need to be followed over a lifetime for one to develop cancer), stratified by cancer site and sex, was estimated. Overall, 1,359,053 incident cancer cases (52.8 % in men) were registered during the surveillance period. The ASR for all malignant tumours was 657.1 per 100,000 among men and 475.5 per 100,000 among women. We documented the highest ASRs for all cancer sites in both sexes (males: 685.7 per 100,000, females: 496.1 per 100,000) in the North, followed by the Center (males: 646.6 per 100,000, females: 488.1 per 100,000), and the South and Islands (males: 626.7 per 100,000, females: 435.4 per 100,000). Mortality rates are less than half that of incidence rates (SMR was 331.8 per 100,000 men and 188.8 per 100,000 women), with negligible differences among Italian areas. One man out of two and 1 women out of three may develop a cancer in their lifetime. Despite incidence and mortality figures in Italy were almost aligned with the ones documented in Europe, our findings recalled the importance for policy-makers to implement national policies and community-based prevention strategies aimed at reducing the cancer burden.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102905"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Half a century of cancer transition in Hungary: A visualization and assessment of mortality dynamics in the Lexis diagram, 1970–2020","authors":"András Wéber ,&nbsp;Freddie Bray ,&nbsp;Mátyás Árvai ,&nbsp;Lászlóné Hilbert ,&nbsp;Dávid Kelemen ,&nbsp;Péter Nagy ,&nbsp;István Kenessey ,&nbsp;Csaba Polgár","doi":"10.1016/j.canep.2025.102925","DOIUrl":"10.1016/j.canep.2025.102925","url":null,"abstract":"<div><h3>Objectives</h3><div>Hungary is among the countries with the highest cancer mortality burden in Europe, consequently there is a crucial need to monitor changes in death rates in the population using appropriate surveillance tools. The Lexis diagram provides a means to depict age, period and cohort influences on long-term cancer mortality trends.</div></div><div><h3>Methods</h3><div>Age-specific mortality rates for six cancer localizations were constructed based on the Deaths Register of the Hungarian Central Statistical Office and the Human Mortality Database, then smoothed (p-splines) within the cells of the Lexis diagram assuming Poisson distribution. After calculating the annual percentage change in mortality rates, the results were visualized using heat maps.</div></div><div><h3>Results</h3><div>Substantial reduction in mortality was observable from the mid-1990s in both sexes as a strong period effect, depicting two distinct epidemiological eras in Hungary. Since 2010, breast cancer mortality in women among ages 70–90 (those born between 1930 and 1950) has been rising. Women born between 1940 and 50 experienced two plateaus in lung cancer mortality, unlike men, emphasizing the delayed nature of the smoking epidemic.</div></div><div><h3>Conclusions</h3><div>The results align with cancer transition patterns observed in similarly developed countries and emphasize a critical need to expand the implementation of effective primary and secondary prevention measures. This includes sustaining organized screening and anti-smoking programs, as well as introducing lung cancer screening with low-dose CT.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102925"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional intake of ω-3 fatty acid intake and clinical grade of prostate cancer","authors":"Nagi B. Kumar ,&nbsp;Saira Bahl ,&nbsp;Daniel Lemay ,&nbsp;Jasreman Dhillon ,&nbsp;Michael Poch ,&nbsp;Brandon Manley ,&nbsp;Roger Li ,&nbsp;Julio Pow-Sang ,&nbsp;Alice Yu ,&nbsp;Junmin Whiting ,&nbsp;Michael J. Schell","doi":"10.1016/j.canep.2025.102959","DOIUrl":"10.1016/j.canep.2025.102959","url":null,"abstract":"<div><h3>Background</h3><div>Recent laboratory and some human studies have shown that ω-3 fatty acids (FA) can inhibit tumor cell growth and induce a local anti-tumor inflammatory response, independently of androgen levels in prostate cancer (PCa) models. Our objective was to conduct a cohort study to evaluate if PCa patients with higher intake of ω-3 FA intake prior to diagnosis will have lower grade prostate tumors as determined by Gleason score at diagnosis compared to those men who consume relative lower quantities of ω-3 FA.</div></div><div><h3>Methods</h3><div>We recruited 172 newly diagnosed men with PCa at the Moffitt Cancer Center, who completed a validated epidemiological, food frequency questionnaire specifically to measure ω-3 fatty acid intake and consented to provide their medical information.</div></div><div><h3>Results</h3><div>Our results indicated that ω-3 FA intake had no impact on grade at diagnosis of PCa. In the multivariate model, ω-3 FA intake indicated a trend toward higher intake being associated with low Gleason grade after adjusting for age and PSA (P &lt; o.25). A novel observation in this study is that, overall, ω-3 fatty acid intake of all men diagnosed with PCa (mean: 2.8 g /week) in this cohort was significantly lower (75 % lower) than the recommendations of the USRDA for optimal ω-3 fatty acid (11.2 g per week).</div></div><div><h3>Conclusion</h3><div>With our understanding of the benefits of ω-3 fatty acid intake for overall health, including its role in preventing prostate carcinogenesis, the overall significantly low dietary intake of ω-3 fatty acid in this cohort may be concerning, requiring further education. Additionally, the role of dietary ω-3 fatty acid intake in the modulation of biomarkers of PCa in general, warrants further studies.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102959"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}